Safety of inhaled long-acting anti-muscarinic agents in COPD

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Postgraduate medicine

• Publication date

  2017-04-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/00325481.2017.1317575PMID 28395575
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tiotropium formulations and safety: a network meta-analysis

  2017cited by this paper
• A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD

  2016cited by this paper
• Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update

  2016influential reference
• A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD.

  2016influential reference
• Vilanterol trifenatate for the treatment of COPD

  2016cited by this paper
• Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study

  2016cited by this paper
• Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease

  2016cited by this paper
• Triple inhaled therapy for chronic obstructive pulmonary disease.

  2016cited by this paper
• Relevance of dosage in adherence to treatment with long-acting anticholinergics in patients with COPD

  2016cited by this paper
• Olodaterol + tiotropium bromide for the treatment of COPD

  2016cited by this paper
• A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?

  2016cited by this paper
• Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.

  2016cited by this paper
• The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study

  2016influential reference
• Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials.

  2016cited by this paper
• Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells

  2016cited by this paper
• Cardiac effects of current treatments of chronic obstructive pulmonary disease.

  2016cited by this paper
• Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

  2016influential reference
• Inhaled bronchodilators and the risk of tachyarrhythmias.

  2015cited by this paper
• Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study

  2015cited by this paper
• Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside.

  2015cited by this paper
• Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis

  2015cited by this paper
• Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date

  2015influential reference
• The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease

  2015cited by this paper
• Aclidinium/formoterol fixed-dose combination for the treatment of chronic obstructive pulmonary disease.

  2015influential reference
• Cardiovascular safety of two bronchodilators' fixed-dose combination: indacaterol and glycopyrronium.

  2015cited by this paper
• Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends.

  2015cited by this paper
• Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease

  2015cited by this paper
• Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.

  2015cited by this paper
• Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.

  2015cited by this paper
• Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)

  2015cited by this paper
• Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis

  2015cited by this paper
• Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD

  2015cited by this paper
• Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease

  2015cited by this paper
• FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.

  2015cited by this paper
• A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD.

  2015influential reference
• Anticholinergic Medications and Risk of Community‐Acquired Pneumonia in Elderly Adults: A Population‐Based Case–Control Study

  2015cited by this paper
• Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy.

  2015cited by this paper
• Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial

  2015influential reference
• Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol

  2015influential reference
• Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study—a randomised controlled trial

  2015cited by this paper
• Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD

  2015cited by this paper
• Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)

  2015cited by this paper
• Tiotropium HandiHaler® and Respimat® in COPD: a pooled safety analysis

  2015cited by this paper
• Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data

  2015cited by this paper
• Impact of Long-Acting Bronchodilators and Exposure to Inhaled Corticosteroids on Mortality in COPD: A Real-Life Retrospective Cohort Study

  2014cited by this paper
• Umeclidinium/Vilanterol: A Review of Its Use as Maintenance Therapy in Adults with Chronic Obstructive Pulmonary Disease

  2014influential reference
• Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases

  2014cited by this paper
• Dose response of umeclidinium administered once or twice daily in patients with COPD: A pooled analysis of two randomized, double‐blind, placebo‐controlled studies

  2014cited by this paper
• Recent advances in COPD disease management with fixed-dose long-acting combination therapies

  2014influential reference
• Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi.

  2014cited by this paper
• Tiotropium and the risk of death in COPD.

  2014cited by this paper
• Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study

  2014cited by this paper
• Translational Study Searching for Synergy between Glycopyrronium and Indacaterol

  2014cited by this paper
• Efficacy and safety of combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD: results of two randomized, double-blind, active-controlled studies

  2014cited by this paper
• Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

  2014cited by this paper
• Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study

  2014cited by this paper
• Tiotropium and the Risk of Death in COPD

  2014cited by this paper
• Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.

  2014cited by this paper
• Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease

  2014cited by this paper
• Tiotropium and the risk of death in COPD.

  2014cited by this paper
• Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.

  2014cited by this paper
• Triple combinations in chronic obstructive pulmonary disease – is three better than two?

  2014cited by this paper
• Umeclidinium/Vilanterol: First Global Approval

  2014cited by this paper
• Tiotropium Respimat inhaler and the risk of death in COPD.

  2013influential reference
• Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease.

  2013cited by this paper
• Safety and tolerability of inhalational anticholinergics in COPD

  2013influential reference
• Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease

  2013cited by this paper
• Ten years of tiotropium: clinical impact and patient perspectives

  2013cited by this paper
• Umeclidinium in patients with COPD: a randomised, placebo-controlled study

  2013cited by this paper
• A new class of bronchodilator improves lung function in COPD: a trial with GSK961081

  2013influential reference
• The Tiotropium Safety and Performance in Respimat® Trial (TIOSPIR®), a large scale, randomized, controlled, parallel-group trial-design and rationale

  2013influential reference
• Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease

  2013cited by this paper
• Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD.

  2013influential reference
• Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD.

  2013cited by this paper
• Long-acting beta-agonists and their association with inhaled corticosteroids in COPD.

  2013cited by this paper
• ACCORD COPD II: A Randomized Clinical Trial to Evaluate the 12-Week Efficacy and Safety of Twice-Daily Aclidinium Bromide in Chronic Obstructive Pulmonary Disease Patients

  2013cited by this paper
• Inhaler Devices for Patients with COPD

  2013influential reference
• Evaluating the safety of COPD medications: an evidence-based review.

  2013cited by this paper
• Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD

  2012cited by this paper
• Efficacy and Safety of a 12-week Treatment with Twice-daily Aclidinium Bromide in COPD Patients (ACCORD COPD I)

  2012cited by this paper
• Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study

  2012cited by this paper
• Muscarinic receptor antagonists: effects on pulmonary function.

  2012cited by this paper
• Pharmacology and Therapeutics of Bronchodilators

  2012cited by this paper
• Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes.

  2012cited by this paper
• 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.

  2012cited by this paper
• The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease

  2012cited by this paper
• Tiotropium versus placebo for chronic obstructive pulmonary disease.

  2012cited by this paper
• Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials

  2012influential reference
• Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial

  2012cited by this paper
• Teaching inhaler use in chronic obstructive pulmonary disease patients

  2012cited by this paper
• Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

  2012cited by this paper
• Dual-pharmacology muscarinic antagonist and β₂ agonist molecules for the treatment of chronic obstructive pulmonary disease.

  2011cited by this paper
• Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials

  2011cited by this paper
• Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial

  2011influential reference
• Discovery of muscarinic acetylcholine receptor antagonist and beta 2 adrenoceptor agonist (MABA) dual pharmacology molecules.

  2011cited by this paper
• Tiotropium for Treatment of Stable COPD: A Meta-analysis of Clinically Relevant Outcomes

  2011cited by this paper
• Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs.

  2011cited by this paper
• Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

  2011cited by this paper
• Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients.

  2010cited by this paper
• Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety

  2010cited by this paper

• Urticaire à l’uméclidinium bromure inhalé

  2025cites this paper
• SUL-151 Decreases Airway Neutrophilia as a Prophylactic and Therapeutic Treatment in Mice after Cigarette Smoke Exposure

  2021cites this paper
• Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies

  2020cites this paper
• The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease

  2018cites this paper